X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GTB-3650 is a 2nd generation nanobody TriKE®, that binds the CD16 receptor on NK cells. It's IND application is submitted after the preclinical studies for the treatment of CD33+ leukemia, including r/r acute myelogenous leukemia & high-risk myelodysplastic syndrome.
Lead Product(s): GTB-3650
Therapeutic Area: Oncology Product Name: GTB-3650
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
Details:
Preclinical data to be presented demonstrate that iPSC-derived, MICA/B-targeted CAR NK cells induced potent activity against AML cell line HL60, and further enhancement of activity was achieved in combination with GTB-3650 through antibody-dependent cellular cytotoxicity.
Lead Product(s): GTB-3650,CAR NK Cell Therapy
Therapeutic Area: Oncology Product Name: GTB-3650
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Fate Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
GTB-3550 is a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and human IL-15.
Lead Product(s): GTB-3550
Therapeutic Area: Oncology Product Name: GTB-3550
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
GTB-5550 TriKE is a tri-specific molecule composed of a dual camelid nanobody that binds the CD16 receptor on NK cells, the single chain variable fragment (scFv) of an anti-B7H3 antibody, and human IL-15.
Lead Product(s): GTB-5550
Therapeutic Area: Oncology Product Name: GTB-5550
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
GTB-3650 is the Company's lead second-generation Tri-Specific Killer Engager TriKE ® program currently in preclinical development for the treatment of relapsed/refractory acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Lead Product(s): GTB-3650
Therapeutic Area: Oncology Product Name: GTB-3650
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cytovance Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 30, 2022
Details:
GTB-7550 (CAM-161519) is Company’s CD19-targeted TriKE targeted against B-cell lymphomas and is part of GT Biopharma’s portfolio of TriKE product candidates being investigated in several preclinical models against a broad class of solid tumors and hematological cancers.
Lead Product(s): GTB-7550
Therapeutic Area: Oncology Product Name: CAM-161519
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
GTB-5550 is the Company’s B7H3-targeted tri-specific killer engager (TriKE) and is part of GT Biopharma’s portfolio of TriKE product candidates being investigated in several preclinical models against a broad class of solid tumor cancers.
Lead Product(s): GTB-5550
Therapeutic Area: Oncology Product Name: GTB-5550
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2022
Details:
NK cell mediated killing increased statistically significantly across all multiple myeloma cell lines tested. Combination therapy with GTB-5550 and anti-cancer agent showed enhanced killing as compared to NK cells or TriKE alone.
Lead Product(s): GTB-5550
Therapeutic Area: Oncology Product Name: GTB-5550
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
Details:
The pre-clinical evidence suggests, despite the difference in circulating immune cells of Stage IVB NSCLC patients, mesothelin-targeted Tri-specific Killer Engager can work alongside current standard of care and provide benefit even in the hypoxic environment of a solid tumor.
Lead Product(s): Tri-specific NK-cell Engager
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
GTB-3550 is a single-chain, trispecific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti- CD16 and anti-CD33 antibodies and a modified form of IL-15.
Lead Product(s): GTB-3550
Therapeutic Area: Oncology Product Name: GTB-3550
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
